Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia

Abstract

Distinguishing between aplastic anemia (AA) and hypoblastic myelodysplastic syndrome (hMDS) with a low percentage of bone marrow (BM) blasts (<5%) can be difficult due to the overlap in clonality and a spectrum of genetic alternations between the two subtypes of diseases. However, due to recent advances in DNA sequencing technology, both spectrum and frequency of mutations can be accurately determined and monitored by next-generation sequencing (NGS) at initial diagnosis and during immunosuppressive therapy (IST) in patients with AA or hMDS. This improvement in acquiring a patient’s genetic status and clonal evolution can provide more proper, precise, and on-time information to guide disease management, which is especially helpful in the absence of traditional morphologic/cytogenetic evidence.

Keywords

aplastic anemia / hypoblastic myelodysplastic syndrome / immunosuppressive therapy / next-generation sequencing

References

[1] YoungNS, MaciejewskiJ. The pathophysiology of acquired aplastic anemia. N Engl J Med, 1997, 336(19): 1365-1372

[2] MarisavljevicD, CemerikicV, RolovicZ, et al.. Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol, 2005, 22(2): 169-175

[3] BabushokDV, PerdigonesN, PerinJC, et al.. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet, 2015, 208(4): 115-128

[4] YoshizatoT, DumitriuB, HosokawaK, et al.. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med, 2015, 373(1): 35-47

[5] HeuserM, SchlarmannC, DobbernackV, et al.. Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica, 2014, 99(9): e165-e167

[6] KulasekararajAG, JiangJ, SmithAE, et al.. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood, 2014, 124(17): 2698-2704

[7] JaiswalS, FontanillasP, FlannickJ, et al.. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med, 2014, 371(26): 2488-2498

[8] XieM, LuC, WangJ. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med, 2014, 20(12): 1472-1478

[9] GenoveseG, KahlerAK, HandsakerRE, et al.. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med, 2014, 371(26): 2477-2487

[10] AfableMG2nd, TiuRV. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program, 2011, 2011: 90-95

[11] OgawaS. Clonal hematopoiesis in acquired aplastic anemia. Blood, 2016, 128(3): 337-347

[12] ShlushLI, ZandiS, MitchellA, et al.. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 2014, 506(7488): 328-333

[13] HuangJ, GeM, LuS, et al.. Mutations of ASXL1 and TET2 in aplastic anemia. Haematologica, 2015, 100(5): e172-e175

[14] LaneAA, OdejideO, KoppN, et al.. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia, 2013, 27(4): 968-971

[15] YoshidaK, SanadaM, ShiraishiY, et al.. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 2011, 478(7367): 64-69

[16] MakishimaH, YoshizatoT, YoshidaK, et al.. Dynamics of clonal evolution in myelodysplastic syndromes, 2017, 49(2): 204-212

[17] BejarR, StevensonK, Abdel-WahabO, et al.. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med, 2011, 364(26): 2496-2506

[18] KimSY, Le RademacherJ, AntinJH, et al.. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica, 2014, 99(12): 1868-1875

[19] DammF, ChesnaisV, NagataY, et al.. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122(18): 3169-3177

[20] HaferlachT, NagataY, GrossmannV, et al.. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia, 2014, 28(2): 241-247

[21] MadanV, KanojiaD, LiJ, et al.. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun, 2015, 6: 6042

[22] ItzyksonR, KosmiderO, CluzeauT, et al.. Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 2011, 25(7): 1147-1152

[23] BejarR, LordA, StevensonK, et al.. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 2014, 124(17): 2705-2712

[24] IdossaD, LashoTL, FinkeCM, et al.. Mutations and karyotype predict treatment response in myelodysplastic syndromes. Am J Hematol, 2018, 93(11): 1420-1426

[25] HongJY, SeoJY, KimSH, et al.. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. Anticancer Res, 2015, 35(5): 3081-3089

[26] PasswegJR, GiagounidisAA, SimcockM, et al.. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol, 2011, 29(3): 303-309

[27] MolldremJJ, CaplesM, MavroudisD. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol, 1997, 99(3): 699-705

[28] SteensmaDP, DispenzieriA, MooreSB. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood, 2003, 101(6): 2156-2158

[29] LimZY, KillickS, GermingU, et al.. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia, 2007, 21(7): 1436-1441

[30] KillickSB, MuftiG, CavenaghJD, et al.. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol, 2003, 120(4): 679-684

[31] MalcovatiL, GalliA, TravaglinoE, et al.. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129(25): 3371-3378

[32] SteensmaDP. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. Blood, 2018, 132: 1657-1663

[33] BejarR, StevensonKE, CaugheyBA, et al.. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol, 2012, 30(27): 3376-3382